2. Academic Validation
  3. Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5‑fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma

Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5‑fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma

  • Sci Rep. 2022 Nov 4;12(1):18731. doi: 10.1038/s41598-022-23619-6.
Jun Gong 1,  Shant Thomassian 1,  Sungjin Kim 1,  Gillian Gresham 1,  Natalie Moshayedi 1,  Jason Y Ye 2,  Julianne C Yang 2,  Jonathan P Jacobs 2,  Simon Lo 1,  Nick Nissen 1,  Srinivas Gaddam 1,  Mourad Tighiouart 1,  Arsen Osipov 1,  Andrew Hendifar 3
Affiliations

Affiliations

  • 1 Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
  • 2 The Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA.
  • 3 Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA. Andrew.hendifar@cshs.org.
PMID: 36333397 DOI: 10.1038/s41598-022-23619-6
Figures
Products